| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5929f2d6f4dba84be8dd3a8ba633db12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate |
2001-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1258bbfb0a5c4d8e863f904b54f48bc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_048fd4e3f1d602cafd75520f695be16e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff1ebafff629260699d2a218b5476d8b |
| publicationDate |
2003-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1281754-A1 |
| titleOfInvention |
Hiv-producing cell line and use thereof |
| abstract |
The object of the present invention is to provide a Tncell line capable of continuously producing humannimmunodeficiency virus (HIV) using CC chemokine receptor 5n(CCR5); and being in a state of continuously producingnhuman immunodeficiency virus (HIV) or in a state whereinnhuman immunodeficiency virus (HIV) is latently infecting,nand a method for isolating and producing the T cell line. n The present invention related to T cell line capablencontinuously producing human immunodeficiency virus (HIV)nusing cc chemokine receptor 5 (CCR5) and being in a statenof continuously producing human immunodeficiency virusn(HIV) is latently infecting, a method for screenings by usenof the T cell line of (1) HIV resistant to an agent havingnan anti-HIV activity, (2) an agent having an anti-HIVnactivity, (3) an agent inhibiting the transition of HIVnfrom the latent period into the proliferation period, andn(4) an agent capable of eliminating HIV from T cell line;nand a pharmaceutical composition comprising the agentnobtained by the above screenings of (2) to (4). n A T cell line of the present invention having ancontinuous productivity of human immunodeficiency virusn(HIV) usnig CC Chemokine receptor 5 (CCR5) is useful innscreening for agents or salts thereof for the treatment or nprevention of diseases such as AIDS caused by HIV. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102879566-A |
| priorityDate |
2000-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |